Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been trending up nicely here.....
Earnings on Friday. Halloween. Trick, or treat? lol.....
I think the books are going to look very nice. New acquisition should show new revenue highs. Hope the eps looks good on this new addition. A lot of new tests and testing volume has been added lately as well.
Roth Capital Reiterates Buy On NeoGenomics Following Financing; Sees 34% Upside http://www.smarteranalyst.com/2014/08/21/roth-capital-reiterates-buy-on-neogenomics-following-financing-sees-4-upside/
$NEO recent news/filings
bullish 50-75% in a week on margin or more longer term
wake up neo...
## source: finance.yahoo.com
Thu, 17 Jul 2014 12:50:30 GMT ~ NEOGENOMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/140717/neo8-k.html
*********************************************************
Thu, 17 Jul 2014 11:32:45 GMT ~ NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014
[at noodls] - Company Raises Full-Year Revenue Guidance to $83 - $86 Million FT. MYERS, Fla., July 17, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services ...
read full: http://www.noodls.com/view/44ADEBA849BE16FD5787FC43B3CB9AE4DC4803E3
*********************************************************
Thu, 17 Jul 2014 11:07:02 GMT ~ Q2 2014 Neogenomics Inc Earnings Release - Before Market Open
read full: http://biz.yahoo.com/research/earncal/20140717.html?t=neo
*********************************************************
Thu, 17 Jul 2014 11:07:00 GMT ~ 7:07 am NeoGenomics reports EPS in-line with recent guidance and consensus, beats on revs/guidance; guides Q3/FY14 EPS in-line, revs above consensus
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#neo
*********************************************************
Thu, 17 Jul 2014 11:00:00 GMT ~ NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014
[PR Newswire] - FT. MYERS, Fla., July 17, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2014. ...
read full: http://finance.yahoo.com/news/neogenomics-reports-record-revenues-20-110000646.html
*********************************************************
$NEO charts
basic chart ## source: stockcharts.com
basic chart ## source: eoddata.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NEO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NEO/company-info
Ticker: $NEO
OTC Market Place: Not Available
CIK code: 0001077183
Company name: NeoGenomics, Inc.
Company website: http://www.neogenomics.org
Incorporated In: NV, USA
Business Description: NeoGenomics Laboratories is a specialized genetics laboratory providing the latest diagnostic testing technologies to the pathology and oncology Communities. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories.
$NEO share structure
## source: otcmarkets.com
Market Value: $217,613,853 a/o Jul 16, 2014
Shares Outstanding: 49,683,528 a/o May 02, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$NEO extra dd links
Company name: NeoGenomics, Inc.
Company website: http://www.neogenomics.org
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NEO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NEO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NEO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NEO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NEO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NEO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/news - http://finance.yahoo.com/q/h?s=NEO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NEO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NEO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NEO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NEO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NEO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NEO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NEO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NEO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NEO
DTCC (dtcc.com): http://search2.dtcc.com/?q=NeoGenomics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NeoGenomics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NeoGenomics%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.neogenomics.org
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.neogenomics.org#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.neogenomics.org
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NEO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NEO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NEO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NEO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NEO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001077183&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NEO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NEO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NEO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NEO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NEO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NEO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NEO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NEO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NEO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NEO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NEO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NEO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NEO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NEO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NEO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NEO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NEO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NEO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NEO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NEO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NEO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NEO
$NEO DD Notes ~ http://www.ddnotesmaker.com/NEO
a11k
It's generally not considered pumping when a post starts with the caution that a stock "could take a while to pay off." I mention nothing about a price target and say it probably won't be going anywhere soon. That's not pumping.
I gather you don't like the stock. Fine, feel free to state your reasons. But please don't badger me any more.
NEO could take a while to pay off big, but eventually I think it will. I'm building a position. It's still a growth story, not a value play, but they are marginally profitable. I added at 3.25.
Fourth Quarter 2013 Highlights:
Revenue growth of 23%
Test volume growth of 28%
Gross Profit Margin of 50.0% versus 43.2% last year
Adjusted EBITDA(1) growth of 90%
Net Income of $0.02 per share versus $0.00 last year
So, if they're profitable right now by a margin of .02 per share but expect reductions in reimbursement that will total .04 per share losses in 2014 due to the new FISH regulations, this means it could potentially send Neogenomics back into the unprofitable zone....
I see why it's better to read news and not just the headline....
In December 2013, the Centers for Medicare and Medicaid Services (CMS) issued new guidance through their National Correct Coding Initiative (NCCI) Policy Manual(1) (the “NCCI Manual”) which could potentially change how laboratories account for the quantity of FISH probes being billed to CMS. A newly added Section K, Paragraph 9 of this NCCI Manual directly contradicts previously issued guidance contained in Section J, Paragraph 6 regarding FISH testing, which had established the current practice of reporting and billing one unit of service for each reportable FISH probe(2).
According to the new guideline in Paragraph K(9), if two or more probes are applied to a sample at the same time, a single unit of service is now to be billed, because the two probes are part of the same “probe staining procedure”. Although the definition of “probe staining” is not clear, it appears that the intent is for CMS to reimburse $0 for a second, third or fourth FISH probe contained in the same vial of reagent. As the cost of reagents from suppliers is substantially greater when multiple probes are incorporated, and technician and pathologist time required to perform and analyze the test is significantly greater when multiple probes are involved, the effect of this guideline may be significant.
NeoGenomics, like other laboratory providers, may choose not to perform FISH tests if costs exceed expenses. NeoGenomics believes FISH is an essential test to inform whether cancer is present, define the subtype of cancer, and help Physicians decide how to effectively treat the disease. In the event the language in Paragraph K(9) of the NCCI Manual is not clarified or changed, it would have the effect of reducing reimbursement for a number of the Company’s FISH testing services that utilize multiple FISH probes that have been pre-mixed into the same vial of reagents by the probe suppliers.
NeoGenomics has contacted Medicare carriers, FISH probe suppliers, reimbursement experts and competitors in the lab industry and there seems to be universal confusion about this new guideline. This new policy was promulgated to the laboratory industry without any notice or the opportunity to comment and has an effective date of January 1, 2014. NeoGenomics has written a letter to the Medical Director of the NCCI as well as CMS, requesting clarification on this issue, but it has not yet received a response or had an opportunity to discuss its concerns. A copy of this letter can be accessed through the homepage of the Company’s website by clicking on the button marked “Recent NCCI Edits”.
While the Company is hopeful that the NCCI and CMS will reconsider their current stance, in the event they do not, NeoGenomics would be forced to alter its billing practices for the affected FISH testing services or reconsider providing the affected FISH services for Medicare beneficiaries.
While NeoGenomics is still determining the impacts that might arise from a negative resolution of the NCCI FISH edit issue, the Company preliminarily estimates that it may result in a reduction of approximately $3 million of revenue and $0.04 per share of net income for the full year 2014, and a reduction of approximately $1.0 million of revenue and $0.02 per share of net income for the first quarter of 2014.
Yeah, actually read the whole thing. That issue looks frustrating. Gotta make up for lost revenues
It's not good news that they have to make up $4M in lost revenue if there are no changes to FISH.
zoro---I just found NEO-----you've been here for three years---looks like your time may have come---I'm taking a starting position---hope you are well rewarded. glty
I got in yesterday morning and this stock is running!
You would have done the robot dance? Seems a little off topic for this message board?
Oh wait, you meant "bought".
No, it will rocket back to $4.xx.
Looks like the bottom is being established here. Slow rise back up?
Where's the bottom on this one? Been on my radar for awhile now, had a nice day yesterday but back down today. I'm looking to get in under $2. Their profits are down, but the company as a whole is expanding and growing. I live in Fort Myers, they are adding new buildings and hiring new employees.
NEO enjoying terrific runup since recent 3 mil share offering @ $3 per share. Anyone following NEO? I've held for about 3 years waiting for a breakout, and I'm delighted with recent activity.
Good Morning NEOphytes!
Surf, how the hell are you? Haven't seen you post on biotech values for a while.
I am a long-timer here, in since '08 (I think). The co. is moving right along. Next step is to sustain a share price over $4 so the funds can start buying in. When this happens, I'd expect a share price to go to about $6.
I also expect the co. to start beating their estimates. New sales staff, new HDVY-based Fish analysis that is more cost effective and better, no more reimbursement issues (for now). If the sequester doesn't screw us, we should hit $20 million/qtr by Q4, and $100 million/yr in the combination of Q3 and 4 2014, + Q1 and 2 2015.
Here we go!
aj
PS: Post to Yahoo to getb them to turn their damn message board on!
NEO Video Chart 2/15/2013
http://www.qualitystocks.net/videocharts.php
Good performance indeed:
"Provides Financial Outlook for 2013
Press Release: NeoGenomics, Inc. – 3 hours ago
Email
RecommendTweet
Print
RELATED QUOTES
Symbol Price Change
NEO 3.10 0.25
FT. MYERS, Fla., Feb. 14, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year 2012.
Fiscal Year 2012 Highlights:
50% Test Volume Growth
38% Revenue Growth
181% Increase in Adjusted EBITDA
Net Income of $65K, or $0.00 per Share
Revenue for the full year 2012 was $59.9 million, a $16.4 million or 38% increase over 2011 revenue of $43.5 million on test volume growth of 50%. Average revenue-per-test decreased by 8% as a result of the expiration of the TC Grandfather Clause on June 30th, which resulted in the loss of approximately $2.6 million of revenue in the second half of the year. Despite this major regulatory change, gross margin improved slightly to 44.8% on a full-year basis from 44.7% in 2011. Total operating expenses increased by 29% from 2011, primarily as a result of a $1.7 million increase in R&D expenditures related to new test development, as well as increased personnel, depreciation and bad debt expense associated with the revenue growth. As a percentage of revenue, operating expenses improved to 42.8% in 2012 from 45.6% in 2011. Net income for 2012 was $65,000 or $0.00 per share versus a net loss of $1.2 million or ($0.03) per share in 2011. Adjusted EBITDA for the year improved by $3.9 million or 181% to $6.0 million from $2.1 million in 2011.
Fourth Quarter 2012 Highlights:
35% Test Volume Growth
16% Revenue Growth
36% Increase in Adjusted EBITDA
Net Loss of $113K, or ($0.00) per Share
Revenue for the fourth quarter 2012 was $14.9 million, a $2.0 million or 16% increase over fourth quarter 2011 revenue on test volume growth of 35%. Gross profit increased to $6.5 million, a 10% increase from the fourth quarter 2011. Total operating expenses increased by $780,000 or 14% from last year's fourth quarter, primarily as a result of a $320,000 increase in R&D expenditures related to new test development and increased personnel and depreciation expense. Net loss for the quarter was ($113,000), or ($0.00) per share, versus net income of 152,000, or $0.00 per share in last year's fourth quarter. Adjusted EBITDA improved 36% to $1.4 million versus $1.1 million in the prior year.
Douglas M. VanOort, the Company's Chairman and CEO commented, "We are very proud of our full-year 2012 results. Our industry-leading 50% growth in test volume indicates that we are clearly winning market share. Although the TC Grandfather expiration reduced revenue by $2.6 million in the second half of the year, we were still able to increase revenue by $16 million or 38% versus 2011 with just 18 sales representatives. As importantly, productivity and process improvements allowed us to grow Adjusted EBITDA by 181% versus 2011, or almost five times the revenue growth rate, and post a modest profit for the year. Our team did a phenomenal job of delivering outstanding service, attracting new clients, reducing costs, and introducing important new tests. We believe we can continue to make progress in each of these important areas in 2013."
Mr. VanOort continued, "We are also proud of our 4th quarter results. We continued to make substantial improvements in lab productivity and operating efficiency in the quarter and came very close to returning to quarterly profitability. Lab productivity increased by 15% and Adjusted EBITDA grew by 36% from last year's fourth quarter. The improvements were also significant compared with Quarter 3, 2012 as we reduced our net loss by $800,000 with only a $700,000 increase in revenue."
Mr. VanOort concluded, "We are particularly proud of the level of innovation and new test development that we are accomplishing. In 2012, we introduced 29 new molecular tests, most of which use bi-directional Sanger sequencing, and built our molecular test menu to be one of the most comprehensive in the lab industry. We also launched 10-color flow cytometry and became the first lab in the country to offer this exciting new service on both a global and tech-only basis. In addition, we vastly improved our immunohistochemistry offering with dozens of new antibodies and brought up a new digital imaging platform. We also continued to expand our comprehensive FISH menu with several new test offerings including a promising new test to aid in the diagnosis of Barrett's Esophagus. We expect these new tests to drive substantial growth in 2013, and we expect that continued R&D investments will result in the commercialization of a number of new and innovative genetic tests."
2013 Financial Outlook
The Company also issued preliminary guidance for the full year and fiscal first quarter of 2013 today. For the full year 2013, the Company expects revenue of $68 - $73 million and net income of $0.03 - $0.05 per share. For the fiscal first quarter, the Company expects revenue of $15.3 - $16.0 million and net income of $0.00 to $0.01 per share. This guidance is based on organic growth in the current business and is based on the assumption that there will be no material reimbursement changes during the balance of 2013. The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance. "
7:34AM NeoPharm beats on top and bottom lines; sees Q1 revs slightly below ests; Q1 EPS slightly above; sees both FY13 EPS and revs in-line with consensus (NEO) 2.85 : Reports Q4 net loss of $113K or EPS of $0.00 vs ($0.01) CIQ est; revs increased 16% YoY to $14.9 mln vs 14.7 mln CIQ est.
Fourth Quarter 2012 Highlights:
35% Test Volume Growth
16% Revenue Growth
36% Increase in Adjusted EBITDA
2013 Guidance:
Q1:
Sees Q1 revs of $15.3 -16.0 mln vs $16.4 mln CIQ est
sees Q1 EPS of $0.00-0.01 vs $0.00 CIQ est.
FY13
Sees FY13 revs of $68-73 mln vs $70.8 mln CIQ est
sees FY13 EPS of $0.03-0.05 vs $0.04 CIQ est.
Hello,
I've owned shares since before the split and have .01 shares from 2001. Unfortunately the 1 for 100 split left me with 500 shares LOL!
Still invested, and NEO is a reminder that "sometimes" OTC stocks do prevail.
Congrats on the NAZ listing,
John
NGNM uplisted to the Nasdaq. New ticker NEO.
http://www.otcbb.com/asp/dailylist_detail.asp?d=12/07/2012&mkt_ctg=OTCBB
NGNM has been on a rampage and today is hitting new all time highs. Where will it stop? I remember a mod over at HSM was real high on this company back in the day, looks like he may have been onto something.
http://ichartpennystocks.com/forum/otc-otcbb-pink-sheets-and-over-the-counter-bulletin-boards/ngnm-neogenomics-inc-otcbb/#p359
weeeeeeeeeeeeeeeeeeeee what a day...
nice upgrade this am as well
http://finance.yahoo.com/news/equity-briefing-upgrades-downgrades-august-141802599.html
Craig Hallum is the firm.
Holler!!!!
Lol
Could you provide a name and link to the analyst making the $5.00 call you posted about?
TIA
Imperial Whazoo
Maybe a institution taking some decent gains. No worries,
Unless we see the same size sells tomorrow..But I guess no, small buying should continue.
almost 700k of the volume in 2 transactions at about $2.20 per - don't know if they were buys or sells at that size transaction each.
almost 700k of the volume in 2 transactions at about $2.20 per - don't know if they were buys or sells at that size transaction each.
Tough read on that. I can't help but pay closer attention now. That volume sure means something!
i enjoyed the 2.69 hit this am but am very suspicious of this 800k vol now. hmmmmmmm
yes indeed, $5+ is not out of the picture here...
GL
This company continues to execute their game plan. Steady rise in the price as well as the growth metrics. This one continues to chug along!!
Hitting new 2+ year highs today on heavy volume, probably time to start watching this stock.
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
304
|
Created
|
08/29/02
|
Type
|
Free
|
Moderators |
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
NeoGenomics offers the complete spectrum of diagnostic services in immunohistochemistry, FISH, flow cytometry, cytogenetics, and molecular testing through our nationwide network of laboratories. We are dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |